Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 51

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 51
---
 liquidity or our financial condition will not be adversely affected, as compared to the condition prior to the announcement of the Divestiture if the Divestiture is not consummated. Even if successfully completed, there are certain risks to our stockholders from the Divestiture, including:

| • |     | we may experience a departure of employees, prior to the closing of the Divestiture; |

| • |     | the amount of cash to be paid under the Divestiture Agreement is fixed and will not be adjusted for changes in                                                                                          
 our business, prospects, outlook, financial condition or operating results or in the event of any change in the market price of, analyst estimates of, or projections related to, our common stock; and |

| • |     | if the Divestiture is completed, our stockholders will forego the opportunity to realize the potential long-term 
 value of the successful execution of our current strategy of the FYARRO Business.                                |

The Divestiture is subject to conditions, some or all of which may not be satisfied, or completed on a timely basis, if at all. There can be no guarantees that the Divestiture will be completed. Failure to complete, or unexpected delays in completing, the Divestiture or any termination of the Divestiture Agreement could have an adverse effect on our financial condition and results of operations. The completion of the Divestiture is subject to a number of conditions, including the approval of the Divestiture by our stockholders, which make the completion and timing of the Divestiture uncertain. See the section entitled “ The Divestiture Agreement— Conditions to the Closing of the Divestiture” for a more detailed discussion. The failure to satisfy all of the required conditions could delay the completion of the Divestiture for a significant period of time or prevent it from occurring at all. There can be no assurance that the conditions to the completion of the Divestiture will be satisfied or waived or that the Divestiture will be completed. In addition, either we or Kaken may terminate the Divestiture Agreement under certain circumstances, including if the Divestiture is not completed by the Termination Date. In certain circumstances, upon termination of the Divestiture Agreement, we would be required to pay a termination fee of $3.5 million to Kaken. For further discussion, see the section entitled “ The Divestiture Agreement— Termination Fees and Remedies.” If the Divestiture is not completed, we may be adversely affected and